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RESULTS: Of the 230,738 eligible patients, 29.7% had depres-
sion diagnoses (n = 68,526), 71.4% were female, mean age was
44.6 years, and 77.9% initiated on SSRIs. Using logistic regres-
sion models for the depression cohort, patients initiating on
duloxetine (n = 2061) versus all other initiators were associated
with being older (OR 1.02), having more prior pain diagnoses
(OR 1.11), depression-related diagnoses (OR 1.52), major depres-
sive disorder recurrent episode diagnoses (OR 1.28), pain 
medications (OR 1.27), antidepressants (OR 1.46), and any psy-
chotherapy (OR 1.14) (all p < 0.01). Duloxetine patients also
were more likely to initiate therapy later in the study (OR 1.04;
p < 0.0001) and were prescribed therapy by mental health (OR
2.32) and other specialists (OR 1.40) versus primary care. When
depressive diagnoses were absent, duloxetine patients (n = 2346)
were more likely to be female (OR 1.21; p < 0.001) versus other
antidepressant initiators (n = 162,212). All other factors remained
consistent. Trends over time are necessary to determine the
robustness of results. CONCLUSIONS: In the ﬁrst four months
after the drug’s availability, duloxetine initiators were associated
with worse prior diagnostic and treatment histories. Case mix 
differences should be made when comparing drug cohorts.
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OBJECTIVE: To compare the treatment costs of schizophrenia
patients who relapsed in the European SOHO study with those
who never relapsed over three years. METHODS: The SOHO
study is a 3-year perspective, outpatient observational study of
10,972 patients across 10 European countries. The Clinical
Global Impression (CGI) Scale was used to measure clinical
effectiveness on a scale of 1 (not ill) to 7 (most severely ill). The
deﬁnition of relapse was based on increases in the CGI Scale
and/or inpatient admission. Kaplan-Meier analysis was used to
estimate the relapse rate over three years. The resource use (inpa-
tient, day care, psychiatrist visits and medications) for those who
ever relapsed during the three years of study was compared to
those who never relapsed. UK costs were applied to the resource
use. RESULT: A totla of 6397 patients with complete data on
CGI and resources were used in the analysis. A totla of 2489
(39%) patients relapsed over the 3 years. The total cost for
patients who relapsed (16,724.27 pounds) was higher than those
who did not relapse (7724.93 pounds). 6368.88 pounds (71%)
of cost difference was due to inpatient stays, 2020.13 pounds
was due to day-care, 416.11 pounds due to medications and
194.22 pounds due to psychiatrist visits. The costs will also be
modelled adjusting for patient characteristics and taking account
of the fact that the cost data is not normally distributed. 
CONCLUSION: Relapsed patients used more health care
resources in the treatment for schizophrenia. The cost of antipsy-
chotic treatments which prevent relapse could be offset by the
savings associated with preventing relapse.
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OBJECTIVES: In retrospective claims database studies, deﬁning
the sample often receives less attention than the statistical
methods used in the analysis. However, identifying an appropri-
ate sample is a key step in the analytic process. The current
research was undertaken to identify typical sample selection def-
initions in retrospective claims database studies of mood disor-
ders. METHODS: A PubMed literature search was conducted to
identify January 2000 to September 2005 publications with the
major topic heading of mood disorders and terms such as admin-
istrative data, insurance claims or claims analysis. The criteria
used for sample selection was abstracted from relevant studies.
RESULTS: Forty-seven studies were abstracted, including 10
speciﬁcally focusing on major depressive disorder (MDD), 15 on
depression and 13 on bipolar disorder (BPD). No set of ICD-9-
CM diagnosis codes was used to identify these conditions across
studies. Three studies deﬁned MDD as 296.2 or 293.3 only,
while others included codes for dysthymia (300.4) and depres-
sive disorder not otherwise speciﬁed (311). Some used codes for
adjustment reaction with depressive symptoms (309.0, 309.2).
One study of depression used only 296.2 and 296.3, while
another used nine different 4-digit ICD-9 codes. All BPD studies
that speciﬁed codes used 296.4–296.6, but the inclusion of other
296 codes varied by study. Several publications did not list the
speciﬁc diagnosis codes used. Some studies required at least two
diagnoses, while others required only one. About half the studies
provided little basis for the coding criteria used. CONCLU-
SIONS: A speciﬁc operational deﬁnition of mood disorders was
not evident from the literature. Results of retrospective claims
database studies with different sample selection criteria may
vary, so it is important to assess ﬁndings in light of the sample
deﬁnition.
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OBJECTIVES: Compare adherence and persistence among
patients with bipolar disorder (BPD) initiated on quetiapine
versus other antipsychotics in a state Medicaid system over a 12-
month follow-up period. There are few published economic eval-
uations of quetiapine in comparison with other antipsychotics.
METHODS: Claims data for patients with BPD from a “de-
identiﬁed” Medicaid database. Patients were assigned to queti-
apine (QTP), olanzapine (OLZ), risperidone (RIS), or typical
antipsychotic treatment groups based on ﬁrst prescription ﬁlled
between January 1, 1999 and December 31, 2001. Adherence
was measured using the medication possession ratio (MPR):
days’ supply of antipsychotic divided by the number of days
between prescription ﬁlls. Persistence was deﬁned as total
number of days from initiation of treatment to therapy modiﬁ-
cation (discontinuation, switching, or combination with another
antipsychotic). Adjustment for confounders was undertaken
using ordinary least squares (OLS) and Cox proportional hazard
regression modeling. RESULTS: Mean (±SD) MPRs were 0.71 ±
0.25 for QTP (n = 106), 0.68 ± 0.29 for OLZ (n = 283), 0.68 ±
0.27 for RIS (n = 231), and 0.46 ± 0.34 for typical antipsychotics
(n = 205). Patients initiated on typical antipsychotics were
24.4% less adherent than patients initiated on QTP (p < 0.001).
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Mean persistence (days) was 219.7 for QTP, 200.9 for OLZ,
194.8 for RIS, and 179.2 for typical antipsychotics. Kaplan-
Meier survival curves for the typical antipsychotic group showed
that hazards of therapy modiﬁcation differed within 250 days of
antipsychotic initiation compared with after 250 days of therapy.
Extended Cox regression modeling indicated no signiﬁcant dif-
ferences between antipsychotics in hazards of therapy modiﬁca-
tion within 250 days of initiation. However, patients initiated on
typical antipsychotics were 6.3 times more likely to modify
therapy compared with those initiated on QTP after 250 days of
antipsychotic therapy (p < 0.0001). CONCLUSIONS: Adher-
ence and persistence were similar between atypical antipsychotic
groups. The typical antipsychotic group, however, demonstrated
lower adherence and a greater likelihood of modifying therapy
than the quetiapine cohort.
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OBJECTIVES: To compare annual mental health service utiliza-
tion patterns by level of adherence with antipsychotic medica-
tion in the naturalistic treatment of schizophrenia. METHODS:
Data were drawn from a large prospective naturalistic study of
treatment for patients with schizophrenia in the U.S, conducted
between July 1997 and September 2003. Detailed mental health
resource utilization was systematically abstracted from medical
records and augmented with patients’ self report. Annual 
medication possession ratio (MPR) with any antipsychotic was
calculated, and each participant was categorized into 1 of 3
adherence groups: adherent (MPR >= 80%, N = 1758), partially
adherent (60% ≤ MPR < 80%, N = 36), and non-adherent (MPR
< 60%, N = 216). RESULTS: Adherent participants were least
likely to have any psychiatric hospitalization and emergency
room visits (p < 0.05). Compared to non-adherent, adherent 
participants were also signiﬁcantly more likely to be engaged in
outpatient treatment processes as evident by greater likelihood
of participation in any psychosocial group intervention (p <
0.05) and in any medication management with psychiatrists (p
< 0.05). CONCLUSIONS: Medication adherence levels are asso-
ciated with differential use of psychiatric services. Adherence
appears to be associated with lower risk of hospitalization and
emergency room visits and greater engagement in the outpatient
treatment processes.
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OBJECTIVES: Compare discontinuation patterns across atypi-
cal antipsychotic agents within the ﬁrst year after initiating
therapy among Medicaid patients with schizophrenia.
METHODS: Adult Medicaid recipients diagnosed with schizo-
phrenia and having atypical antipsychotic drug prescription
claims between July 1, 2001 and September 30, 2003 were cat-
egorized into ﬁve groups of initial antipsychotic drug received:
aripiprazole (n = 446); olanzapine (n = 1705); quetiapine (n =
1467); risperidone (n = 1580); and ziprasidone (n = 700). Dis-
continuation was measured using reﬁll patterns, allowing 14-day
gaps between expected reﬁll dates, and compared across starting
drug groups using Chi-Square tests. Multivariate Cox propor-
tional hazards models then explored the simultaneous impact of
age, gender, race, hospitalization in the 6 months prior to initial
therapy, and other concurrent antipsychotic drug use when 
initiating therapy, in addition to being on any one of the ﬁve
mutually exclusive drug groups, on discontinuation. Sensitivity
analysis tested the robustness of results using longer allowable
prescription gaps between reﬁlls, and examining multiple
episodes of atypical antipsychotic use by using different deﬁni-
tions of the index date. RESULTS: Patients starting treatment on
either aripiprazole, risperidone, or ziprasidone were not signiﬁ-
cantly different from olanzapine [HR 1.047, 0.973 and 0.990,
respectively] with respect to discontinuation of therapy. 
Quetiapine was associated with signiﬁcantly higher hazard of
discontinuation [HR 1.130, p = 0.0044] compared to olanzap-
ine. Other covariates associated with signiﬁcantly lower discon-
tinuation rates were being male [HR 0.899, p = 0.0008], older
age [HR 0.997, p = 0.0348] and being on concurrent medication
when initiating therapy [HR 0.225, p < 0.001]. Having previous
hospitalization was associated with signiﬁcantly higher discon-
tinuation rate [HR 1.276, p < 0.001]. These results were robust
across sensitivity analyses. CONCLUSIONS: Patients initiating
on ziprasidone, aripiprazole, risperidone and olanzapine had
similar discontinuation at one year. The higher hazard associated
with quetiapine is consistent with the higher rate of discontinu-
ation observed for quetiapine when compared to olanzapine in
Phase I of the CATIE trial.
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OBJECTIVES: To determine the compliance and persistence to
atypical antipsychotics in the treatment of schizophrenia patients
and associated health care utilization. METHODS: The study
sample was based on NC Medicaid claims database. Patients were
included if they had a diagnosis of schizophrenia (ICD-9 295.XX),
received at least two antipsychotic prescriptions during the period
after index date and were continuously enrolled in NC Medicaid
Program during three month prior and one year post treatment
periods. Medication possession ratio (MPR), persistence and
medication use gap were used as compliance measures. Both
descriptive and multivariate model were conducted. RESULTS:
A total of 450 patients were included. Mean age was 42.3 years.
52.4% were men and 33.1% were blacks. Adherent (0.8 <= PR
<= 0.1), non-adherent (MPR < 0.8) and over-adherent (MPR >
1.1) patients accounted for 34.8%, 45.3%, and 18.9% respec-
tively. Approximately 42.4% of patients had medication use gap,
and the average duration of continuous medication use was 229
days. Adherent patients had fewer hospital admissions and hos-
pital days than nonadherent and overadherent patients (0.57 vs.
1.0 vs. 0.82 admissions; 5.2 vs. 10.0 vs. 5.9 days). Patients with
gaps in medication use had more hospital admissions and hospi-
tal days than those without gaps (1.1 vs. 0.64 admissions; 10.4
vs. 5.3 days). In terms of the risk of hospitalization, nonadher-
ent patients were more likely to be hospitalized than adherent
ones (OD: 1.694, 95% CI: 1.019–2.816). Patients with gaps in
medication use were more likely to be hospitalized (OD: 2.589,
95% CI: 1.633–4.106) and had 11 more hospital days than those
without a gap (p = 0.0275). Patients who stayed on medication
longer were less likely to be admitted to hospitals (OD: 0.998,
95% CI: 0.997–0.999). CONCLUSIONS: The results from this
